Pieris Pharmaceuticals, Inc.

  • Home
  • About
  • Pipeline
  • Investors
    • Overview
    • News & Events
    • Publications
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. For more information about the Company and updates, please visit www.palvellatx.com or follow us on LinkedIn.

Continue
  • News & Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts

First Quarter 2022 Investor Call and Corporate Update

May 11, 2022 8:00 am EDT
Earnings Release
PDF HTML
Audio
Earnings Webcast
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 Pieris Pharmaceuticals, Inc. All Rights Reserved.
Imprint Privacy Policy Disclaimer Sitemap Contact Us Manage Cookie Preferences